Research Article

Meta-Analysis of the Therapeutic Effect of Shenqi Jiangtang Granule on Type 2 Diabetes Mellitus

Ruo-Lan Li,1 Tai-Wei Dong,1 Ji-Gang Wei,2 Feng Gao,1 Min Li,1 Yang Bai,3 Pei-Feng Wei,1,3 and Miao-Miao Xi3

1College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Road, Qindu District, Xianyang, Shaanxi 712046, China
2Tongchuan Mineral Bureau Central Hospital, No. 15, Chuankou Road, Wangyi District, Tongchuan, Shaanxi 727000, China
3The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Weiyang West Road, Qindu District, Xianyang, Shaanxi 712046, China

Correspondence should be addressed to Pei-Feng Wei; peifeng_ad@163.com and Miao-Miao Xi; miaomiaoxi2014@163.com

Received 25 May 2020; Revised 1 July 2020; Accepted 23 July 2020; Published 29 September 2020

Guest Editor: Reggiani Vilela Gonçalves

Copyright © 2020 Ruo-Lan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To systematically evaluate the effectiveness of Shenqi Jiangtang granule (SQJT) in the treatment of type 2 diabetes.

Methods. We searched CNKI, Wanfang Data, VIP, and PubMed databases to collect randomized controlled trials (RCT) of Shenqi Jiangtang granules in the treatment of type 2 diabetes. The search time was from January 2014 to the present. Data were extracted, and quality was evaluated. Metadata analysis of the extracted data was carried out using RevMa5.2 software. The final results are expressed in relative risk (RR), mean difference (MD), and 95% CI. Results. This study included a total of 13 studies, 1160 subjects. Meta-analysis results showed that the test group was better than the control group (RR = 1.26, 95% CI 1.18–1.34, P < 0.00001). The fasting blood glucose, postprandial blood glucose, and glycated hemoglobin of the test group were also significantly better than those of the control group. Conclusion. Shenqi Jiangtang granules have a certain clinical effect and low adverse reaction rate for the treatment or adjuvant treatment of type 2 diabetes. At present, the drug has been widely used in clinical practice, but a large number of large-sample clinical trials are needed to further verify its specific efficacy and safety.

1. Introduction

Diabetes is a metabolic disease characterized by high blood sugar, which is divided into type 1 and type 2. Type 1 diabetes is an autoimmune disease that causes destruction of islet \( \beta \) cells, accounting for about 5%–10% of patients with diabetes [1]. Type 2 diabetes mellitus (T2DM) is also known as adult-onset diabetes. It develops after 35 to 40 years of age and accounts for more than 90% of diabetic patients. This disease is characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both [2]. The pathogenesis of T2DM is more complicated. With the development of social economy and the improvement of people’s living standards, the prevalence of T2DM is rapidly increasing worldwide [3]. Therefore, we believe that the pathogenesis of the disease may have a close relationship with the patient’s own lack of exercise, high-calorie diet, and poor eating habits. According to statistics from relevant data, the number of diabetes patients in 2107 has reached 42.49 million, and approximately 35.21 million people worldwide have impaired glucose tolerance (i.e., they are in prediabetes) [4]. It is emerging as one of the most prevalent human ailments next to cardiovascular diseases and is the sixth leading cause of death worldwide (WHO). It is estimated that, by 2030, the number of people with diabetes worldwide will be close to 550 million [5]. Diabetes is a chronic disease. Patients with long-term high blood sugar will cause more serious complications such as diabetic neuropathy, diabetic nephropathy, and diabetic foot [6, 7] which seriously threaten the patient’s health and quality of life [8]. At present, the treatment of diabetes is mainly through long-term, regular use of drugs to improve the patient’s glucose metabolism [9, 10]. The first-line drugs used in clinical treatment of T2DM mainly include
2.1. Type of Study. The literature of clinical RCTs related to Shenqi Jiangtang granules in the treatment of type 2 diabetes was considered, whether blind or not.

2.1.2. Research Object. Patients who meet the “Chinese Type 2 Diabetes Prevention and Treatment Guidelines (2017 Version)” [18] and are diagnosed with type 2 diabetes, that is, patients with polydipsia, polyphagia, polyuria, and body mass decline, random blood glucose ≥11.1 mmol/L, fasting Blood glucose (FBG) ≥7.0 mmol/L, and/or 2 hours post-prandial blood glucose (P2h BG) ≥11.1 mmol/L, were included.

2.1.3. Intervention. The patients in the control group were not given treatment or simply treated with Western medicine. The patients in the test group were treated with Shenqi Jiangtang granules on the basis of the control group.

2.1.4. Outcome Indicators. The main outcome indicators were effectiveness, fasting blood glucose (FBG), postprandial blood glucose (PPG), glycated hemoglobin (HbA1c), and adverse reaction rate.

2.1.5. Exclusion Criteria. A large number of repeated publications; non-RCT studies (including clinical case reports, relevant literature reviews, animal pharmacological experiments, and non-RCT clinical trials and other types of literature); the literature with incomplete outcome indicators; the literature that cannot extract data; and other non-compliant inclusions standard literature were the exclusion criteria.

2.2. Document Retrieval Process. Relevant medical journals in Chinese and English databases, such as the China Knowledge Network (CNKI), Wanfang Data Knowledge Platform (Wanfang Data), VIP Database, and PubMed, were searched from 2014 to the present. The retrieval process follows the PICOS principle, namely, P: type 2 diabetes; I: Shenqi Jiangtang granules + Western medical method; C: western medical method; O: type 2 diabetes-related indicators; and S: randomized controlled trial. We set the following keywords as search strategies: type 2 diabetes, Shenqi Jiangtang granules, lower blood sugar, and clinical trials, and we use this search strategy to prescreen Chinese and English databases, further optimize the search keywords based on the search results, and record the final search literature.

2.3. Data Extraction and Quality Evaluation of the Literature Methodology. After collecting and summarizing the documents retrieved above, according to the established inclusion and exclusion criteria, combined with the systematic review method of the Cochrane Collaboration Network to select qualified documents, relevant information will be extracted from the qualified documents after screening. Through the RCT quality assessment standard of the Cochrane Collaboration Network, the methodological quality of the included documents is evaluated, and the documents are included in the following 7 aspects: random method, allocation concealment, blind implementation, concealment of outcome indicators, and integrity of outcome indicators.

2.4. Statistical Methods. RevMan 5.2 software was used for statistical analysis of the extracted data. Binary variables and continuous variables were calculated using relative risk (RR) and mean (MD), respectively, and a 95% confidence interval (CI) was calculated. When the combined data have no significant heterogeneity (P > 0.10 or I² ≤ 50%), the fixed-effect model is used for analysis; when the combined data have significant heterogeneity (P ≤ 0.10 or I² ≥ 50%), then the random effects model is used for analysis. P < 0.05 was considered statistically significant.

2.5. Evidence Quality Evaluation. GraphPad Prism 6 software was used to input and quantify the quality of the included outcome indicators [19]. The GRADE evidence quality evaluation divides the outcome indicators into 3 grades, of which 1–3 are unimportant outcome indicators, 4–6 are important outcome indicators, and 7–9 are key outcome indicators; RCT is set as the high quality of intervention effect estimation evidence, and observational


3. Results

3.1. Literature Screening Process and Results. A total of 516 related documents were retrieved through the system. After screening duplicate documents, limiting publication time, and reading titles and abstracts, a total of 503 articles were excluded, and finally, 13 articles were included. The specific screening process is shown in Figure 1.

3.2. Basic Information Included in the Literature. All studies are conducted in China and are RCT experiments. Table 1 shows the detailed characteristics of all studies, such as age, sex ratio, intervention methods, treatment cycle, and outcome indicators. A total of 1160 patients were tested in this study, including 580 in the test group (T) and 580 in the control group (C).

3.3. Inclusion of Literature Quality Evaluation. Refer to the bias risk assessment standard provided by the Cochrane Collaboration Network to conduct randomization, allocation concealment, blind implementation, blindness of outcome indicators, completeness of outcome indicators, and other 7 aspects of bias studies for the included documents. It is expressed in three ways: low risk, high risk, and unclear. The results are shown in Figure 2.

3.4. Meta-Analysis Results

3.4.1. Meta-Analysis Based on the Effectiveness of Clinical Treatment. Among the 13 studies included, 9 articles included statistics on the total effectiveness of the experimental group and the control group, and the analysis showed no heterogeneity (DF = 8, P = 0.95, I² = 0%), so a fixed-effect model is used. Meta-analysis results are shown in Figure 3. The combined RR value of the included literature is 1.26 (95% CI (1.18, 1.34)). As shown in Figure 4, we performed a subgroup analysis of the included studies according to the type of treatment drug in the control group. The results showed that there was no heterogeneity in each subgroup. The results show that the total effective rate of the experimental group is higher than that of the control group, and the difference is statistically significant (P < 0.00001).

3.4.2. Meta-Analysis Based on Fasting Blood Glucose Indicators. A total of 12 literature were included in the fasting blood glucose test. The results of the study showed that there was no heterogeneity between the studies (DF = 11, P = 0.77, I² = 0%). The fixed-effect model was used. Figure 5 shows that the fasting blood glucose control degree of the Shenqi Jiangtang granules combined medication group was better than that of the control group, MD = −1.18 (95% CI (−1.29, −1.06)), and the results of the test group and the control group were statistically different (P = 0.00001). As shown in Figure 6, we conducted a subgroup analysis of the included studies based on the type of therapeutic drugs in the control group. The results showed that there was no heterogeneity in each subgroup. The results showed that the fasting blood glucose index of the experimental group was lower than that of the control group, and the difference was statistically significant.

3.4.3. Meta-Analysis Based on Postprandial Blood Glucose Indicators. A total of 12 literature were included in the postprandial blood glucose test, and the results showed that there was no heterogeneity (DF = 11, P = 0.18, I² = 27%); a fixed-effect model was used. Figure 7 shows that Shenqi Jiangtang granules degree of postprandial blood glucose control in the combined medication group was better than that in the control group, MD = −1.74 (95% CI (−1.95, −1.53)). The results of the test group and the control group were statistically different (P < 0.00001) (see Figure 7). As shown in Figure 8, we conducted a subgroup analysis of the included studies based on the type of therapeutic drugs in the control group. The results showed that there was no heterogeneity in each subgroup. The results showed that the postprandial blood glucose index of the experimental group was lower than that of the control group, and the difference was statistically significant.

3.4.4. Meta-Analysis Based on the Glycated Hemoglobin Index. A total of 12 literature were included in the detection of outcome indicators for glycated hemoglobin. The results of the study showed that there was no heterogeneity between
| Reference               | Sample size (C/T) | Gender (male/female) | Age (range, mean) | Treatment method | Treatment cycle (week) | Measurement index |
|-------------------------|-------------------|----------------------|-------------------|------------------|------------------------|-------------------|
| Zhang et al., 2019 [21] | 60/60             | T: 31/33; C: 29/27   | T: 45–67 (57.13 ± 9.86) C: 42–69 (57.46 ± 9.74) | T: SQJT+ Metformin + Glimepiride C: Metformin + Glimepiride | 12 | 1, 2, 3, 4 |
| Sui 2019 [22]          | 52/52             | T: 30/31; C: 22/21   | T: 39–68 (54.31 ± 11) C: 38–67 (53.2 ± 4.7) | T: SQJT + Metformin + Rosiglitazone C: Metformin + Rosiglitazone | 12 | 1, 2, 4 |
| Liu and Gao, 2017 [23] | 20/20             | T: 23/10; C: 14/10   | T: 41–65 (56.55 ± 17) C: 42–65 (55.3 ± 7.36) | T: SQJT + Metformin C: Metformin | 12 | 1, 2, 3, 4 |
| Sun, 2017 [24]         | 48/48             | T: 28/30; C: 20/18   | T: 38–64 (56.27 ± 4.61) C: 36–62 (54.15 ± 4.29) | T: SQJT + Metformin C: Metformin | 8 | 1, 2, 3, 4 |
| Wang, 2016 [25]        | 69/69             | T: 43/31; C: 26/28   | T: 25–65 (54.3 ± 3.2) C: 26–65 (53.2 ± 3.4) | T: SQJT + Metformin + Insulin glargine C: Metformin + Insulin glargine | 12 | 1, 2, 3, 4 |
| Yang, 2017 [26]        | 40/40             | T: 21/22; C: 19/18   | T: 42–65 (55.8 ± 8.9) C: 45–64 (55.4 ± 6.8) | T: SQJT + Metformin C: Metformin | 24 | 2, 3, 4 |
| Chen, 2018 [27]        | 52/52             | T: 32/24; C: 20/16   | T: 26–63 (55.2 ± 3.5) C: 27–60 (54.3 ± 3.7) | T: SQJT + Metformin C: Metformin | 12 | 2, 3, 4 |
| Fan and Gao, 2014 [28] | 40/40             | T: 22/24; C: 20/16   | T: 42–74 C: 40–73 | T: SQJT + Metformin C: Metformin | 12 | 1, 2, 3, 4 |
| Zhang, 2019 [29]       | 49/49             | T: 29/31; C: 20/18   | T: 40–75 (59.18 ± 7.66) C: 43–74 (60.27 ± 6.34) | T: SQJT + Metformin C: Metformin | 12 | 3, 4 |
| Song, 2018 [30]        | 36/36             | T: 21/20; C: 15/16   | T: 43–76 (59.12 ± 10.83) C: 41–74 (58.94 ± 10.15) | T: SQJT + Liraglutide C: Liraglutide | 12 | 1, 2, 3, 4 |
| Li, 2015 [31]          | 42/42             | T: 27/26; C: 15/16   | T: 53–68 (63.1 ± 6.6) C: 54–69 (62.8 ± 6.2) | T: SQJT + Repaglinide C: Repaglinide | 4 | 1, 2, 3, 4 |
| Wang, 2013 [32]        | 42/42             | T: 26/27; C: 16/15   | T: 35–66 (45.9 ± 7.4) C: 33–63 (43.5 ± 5.2) | T: SQJT + Metformin C: Metformin | 8 | 1, 2, 3, 4 |
| Liu, 2018 [33]         | 30/30             | T: 14/13; C: 16/17   | T: 60–76 (67.2 ± 9.4) C: 60–78 (66.8 ± 10.2) | T: SQJT + Metformin C: Metformin | 12 | 2, 3 |

Note: 1. Efficient; 2. FBG; 3. PBG; 4. HbA1c.
the studies (DF = 11, P = 0.08, $I^2 = 39\%$). A fixed-effect model was used. Figure 9 shows that the control level of glycated hemoglobin in the Shenqi Jiangtang granules combined medication group was better than that in the control group, MD = −1.13 (95% CI (−1.24, −1.01)), and the results of the experimental group and the control group were statistically different ($P < 0.00001$). As shown in Figures 10 and 11, we conducted a subgroup analysis of the included studies based on the type of therapeutic drugs in the control group. The results showed that the metformin control group was heterogeneous, so a random effect model was used. The heterogeneity effect is small and may be caused by clinical heterogeneity. There was no heterogeneity in the remaining subgroups. The results showed that the glycated hemoglobin index of the experimental group was lower than that of the control group, and the difference was statistically significant.

3.4.5 Meta-Analysis of Adverse Reactions. Adverse events were mentioned in the 4 articles included, and the results showed no heterogeneity between studies (DF = 3, $P = 0.6$, $I^2 = 0\%$), using a fixed-effect model. Figure 12 shows the combination of Shenqi Jiangtang granules. The incidence of adverse reactions in the treatment group was lower than that in the control group MD = 0.21 (95% CI (0.08, 0.51)), and there was a significant difference between the experimental group and the control group ($P = 0.0006$). As shown in Figure 13, we conducted a subgroup analysis of the included studies based on the type of therapeutic drugs in the control group. The results showed that there was no heterogeneity in each subgroup. The results showed that the adverse reactions of the experimental group were lower than that of the control group, and the difference was statistically significant.

3.4.6 Sensitivity Analysis. Sensitivity analysis of the efficacy, fasting blood glucose, postprandial blood glucose, glycated hemoglobin, and adverse reaction rate of Shenqi Jiangtang granules in the treatment of type 2 diabetes was performed by changing the effect model and removing the larger or smaller proportion of the weights. The results of the study did not change significantly, indicating
that our results were statistically reliable, as shown in Table 2.

3.4.7. Evaluation of Publication Bias Based on the Total Effective Clinical Efficacy. Evaluation of the total effectiveness of the included literature is performed, as shown in Figure 14, and the funnel chart results suggest that the study data of Shenqi Jiangtang granules combined with conventional Western medicine in the treatment of type 2 diabetes are more authentic and less likely to be biased.

3.5. Evaluation of the Evidence Quality. GraphPad Prism 6 was used to evaluate the quality of the included literature. The total effective rate of treatment is a key outcome indicator, and fasting blood glucose, postprandial blood glucose, and glycated hemoglobin are important outcome indicators. The grading chart of evidence quality of each outcome index is shown in Figure 15. All included documents are RCT experiments, and there is no obvious publication bias.

4. Discussion

As a high-risk group, type 2 diabetes patients are increasingly valued by more and more medical workers, which has also caused a lot of attention. The patient’s body has been in a disorder of blood glucose and blood lipid metabolism for a long time, and the possibility of various chronic complications has also increased significantly [34]. Western medicine hypoglycemic drugs achieve a good hypoglycemic effect by enhancing the body’s consumption of glucose, inhibiting its absorption and production [35]. However, in the long-term observation of Western medicine treatment, it has been found that insulin secreted and synthesized by islet β cells under physiological conditions has no obvious hypoglycemic effect, the feedback of insulin concentration increases, and the patient’s blood glucose level increases significantly. Long-term resistance of the islet function not only affects the hypoglycemic effect of the drug but also causes certain damage to islet β cells, resulting in functional exhaustion [36]. “Su Wen-Singular Disease” records that “this person must eat sweet and fat but also fat so his qi...
overflown and turned to thirst.” Obesity is the basis for the onset of type 2 diabetes, and phlegm turbidity, dampness, and heat content are the initial factors. Phlegm turbidity, dampness, and heat obstruction are scorching, soil stagnation, spleen loss of health, liver loss and drainage, and water valley fineness. Stagnation of blood is an important part of the rise of blood sugar and its incidence, and blood stasis is the main cause of various comorbidities [37]. The main components of Shenqi Jiangtang granules are ginseng, ginsenosides, Astragalus, Ophiopogon japonicus, raspberry,
trichosanthin, Rehmannia glutinosa, poria, medlar, Alisma, Schisandra, and yam. Modern pharmacological studies have shown that ginsenoside can repair islet β cells, promote insulin release, and can inhibit alloxan and improve hyperglycemia [38]. Astragalus can regulate the body’s immunity, scavenge oxygen free radicals, protect vascular endothelial cells, increase insulin sensitivity, weaken insulin resistance, and regulate blood lipid and blood glucose. Poria can lower blood sugar and increase the function of islet β cells. Studies have shown that the use of poria can increase the antioxidant capacity of kidneys in type 2 diabetic mice and plays a protective role in the kidneys. Ginseng can also
| Study or subgroup | Experimental Mean | Experimental SD | Experimental Total | Control Mean | Control SD | Control Total | Weight (%) | IV, fixed, 95% CI Mean difference | IV, fixed, 95% CI Mean difference |
|------------------|------------------|-----------------|-------------------|--------------|------------|--------------|------------|-----------------------------------|---------------------------------|
| Caixia Wang 2016 | 6.16             | 1.12            | 69                | 7.57         | 1.14       | 69           | 9.7        | -1.41 [−1.79, −1.03]               |                                 |
| Changhong Song 2018 | 6.42           | 1.23            | 36                | 7.52         | 1.71       | 36           | 2.9        | -1.10 [−1.79, −0.41]               |                                 |
| Fengling Ji 2019 | 6.2              | 1.02            | 52                | 7.56         | 1.14       | 52           | 8.0        | -1.36 [−1.78, −0.94]               |                                 |
| Hua Yang 2017    | 6.35             | 0.67            | 40                | 7.14         | 0.84       | 40           | 12.4       | -0.79 [−1.12, −0.46]               |                                 |
| Huiping Liu 2017 | 8.14             | 0.92            | 20                | 9.35         | 1.14       | 20           | 3.3        | -1.21 [−1.85, −0.57]               |                                 |
| Lei Zhang 2019   | 8.11             | 0.66            | 60                | 7.26         | 0.79       | 60           | 20.3       | -1.15 [−1.41, −0.89]               |                                 |
| Shiyu Chen 2018  | 5.96             | 1.02            | 52                | 7.35         | 1.06       | 52           | 8.6        | -1.39 [−1.79, −0.99]               |                                 |
| Wei Li 2015      | 7.13             | 0.68            | 42                | 8.23         | 0.86       | 42           | 12.5       | -1.10 [−1.43, −0.77]               |                                 |
| Yanzhao Zhang 2019 | 6.12         | 1.23            | 49                | 6.77         | 1.55       | 49           | 4.5        | -0.65 [−1.20, −0.10]               |                                 |
| Yingli Fan 2017  | 5.7              | 0.71            | 40                | 7             | 0.82       | 40           | 12.2       | -1.30 [−1.64, −0.96]               |                                 |
| Yue Sun 2017     | 6.54             | 1.58            | 48                | 7.27         | 1.73       | 48           | 3.1        | -0.73 [−1.39, −0.07]               |                                 |
| Zaiping Wang 2013 | 6.72            | 1.65            | 42                | 7.14         | 1.77       | 42           | 2.6        | -0.42 [−1.15, −0.31]               |                                 |

Total (95% CI) 550 550 100.0  -1.13 [−1.24, −1.01]  
Heterogeneity: $\chi^2 = 17.92, df = 11 (P = 0.08); I^2 = 39\%$
Test for overall effect: $Z = 18.82 (P < 0.00001)$

**Figure 9:** Forest map of HbA1c of Shenqi Jiangtang granule in the treatment of type 2 diabetes mellitus.

| Study or subgroup | Experimental Mean | Experimental SD | Experimental Total | Control Mean | Control SD | Control Total | Weight (%) | IV, random, 95% CI Mean difference | IV, random, 95% CI Mean difference |
|------------------|------------------|-----------------|-------------------|--------------|------------|--------------|------------|-----------------------------------|---------------------------------|
| 1.9.1 Metformin  |                  |                 |                   |              |            |              |           |                                   |                                 |
| Hua Yang 2017    | 6.35             | 0.67            | 40                | 7.14         | 0.84       | 40           | 19.7       | -0.79 [−1.12, −0.46]               |                                 |
| Huiping Liu 2017 | 8.14             | 0.92            | 20                | 9.35         | 1.14       | 20           | 10.9       | -1.21 [−1.85, −0.57]               |                                 |
| Shiyu Chen 2018  | 5.96             | 1.02            | 52                | 7.35         | 1.06       | 52           | 17.4       | -1.39 [−1.79, −0.99]               |                                 |
| Yanzhao Zhang 2019 | 6.12         | 1.23            | 49                | 6.77         | 1.55       | 49           | 12.9       | -0.65 [−1.20, −0.10]               |                                 |
| Yingli Fan 2017  | 5.7              | 0.71            | 40                | 7             | 0.82       | 40           | 19.6       | -1.30 [−1.64, −0.96]               |                                 |
| Yue Sun 2017     | 6.54             | 1.58            | 48                | 7.27         | 1.73       | 48           | 10.4       | -0.73 [−1.39, −0.07]               |                                 |
| Zaiping Wang 2013 | 6.72            | 1.65            | 42                | 7.14         | 1.77       | 42           | 9.2        | -0.42 [−1.15, −0.31]               |                                 |
| Subtotal (95% CI) | 291              |                 | 291               |              |            |              | 100.0      | -0.98 [−1.25, −0.71]               |                                 |

Total (95% CI) 291 291 100.0  -0.98 [−1.25, −0.71]  
Heterogeneity: $\tau^2 = 0.07; \chi^2 = 13.15, df = 6 (P = 0.04); I^2 = 54\%$
Test for overall effect: $Z = 7.11 (P < 0.00001)$

**Figure 10:** Forest map of subgroup analysis on the HbA1c of Shenqi Jiangtang granule in the treatment of type 2 diabetes mellitus.

| Study or subgroup | Experimental Mean | Experimental SD | Experimental Total | Control Mean | Control SD | Control Total | Weight (%) | IV, fixed, 95% CI Mean difference | IV, fixed, 95% CI Mean difference |
|------------------|------------------|-----------------|-------------------|--------------|------------|--------------|------------|-----------------------------------|---------------------------------|
| 1.9.2 Metformin assisted other Western medicine |                    |                 |                   |              |            |              |           |                                   |                                 |
| Caixia Wang 2016 | 6.16             | 1.12            | 69                | 7.57         | 1.14       | 69           | 18.1       | -1.41 [−1.79, −1.03]               |                                 |
| Fengling Ji 2019 | 6.2              | 1.02            | 52                | 7.56         | 1.14       | 52           | 14.9       | -1.36 [−1.78, −0.94]               |                                 |
| Lei Zhang 2019   | 6.11             | 0.66            | 60                | 7.26         | 0.79       | 60           | 38.0       | -1.15 [−1.41, −0.89]               |                                 |
| Subtotal (95% CI) | 181              |                 | 181               |              |            |              | 71.1       | -1.26 [−1.45, −1.07]               |                                 |

Heterogeneity: $\chi^2 = 1.52, df = 2 (P = 0.47); I^2 = 0\%$
Test for overall effect: $Z = 12.97 (P < 0.00001)$

**Figure 11:** Forest map of subgroup analysis on the HbA1c of Shenqi Jiangtang granule in the treatment of type 2 diabetes mellitus.
increase the sensitivity of insulin and effectively regulate blood sugar and blood lipids; in addition, it can increase the antioxidant capacity of the myocardium, protect vascular endothelial cells, and inhibit cardiomyocyte apoptosis [39]. *Ophiopogon japonicus* has a strong lipid-lowering effect and can reduce the content of TC in blood [40]. *Schisandra can*
**Figure 14:** Funnel plot of the total efficacy of SQJT granules compared with conventional medicines.

| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No. of Participants (studies) | Quality of the evidence (GRADE) | Comments |
|----------|----------------------------------------|--------------------------|------------------------------|-------------------------------|----------|
| Efficient | Study population | RR 1.26 (1.18 to 1.34) | 818 (9 studies) | moderate | 1 |
|          | Assumed risk | Control | Shenqi Jiangtang granule + conventional treatment | | | |
|          | No. of Participants | (studies) | | | |
|          | 731 per 1000 | 921 per 1000 (863 to 980) | | | |
|          | Moderate | | | | |
|          | 731 per 1000 | 921 per 1000 (863 to 980) | | | |
| FBG      | The mean fbg in the intervention groups was 1.18 lower (1.29 to 1.06 lower) | | 1062 (12 studies) | moderate | 1 |
| FBG      | The mean pbg in the intervention groups was 1.77 lower (2.03 to 1.51 lower) | | 1120 (12 studies) | moderate | 1 |
| Hba1c    | The mean hba1c in the intervention groups was 1.11 lower (1.27 to 0.95 lower) | | 1100 (12 studies) | moderate | 1 |
| Adverse reaction rate | Study population | RR 0.21 (0.08 to 0.51) | 424 (4 studies) | moderate | 1,2 |
|          | 123 per 1000 | 26 per 1000 (10 to 63) | | | |
|          | Moderate | | | | |
|          | 125 per 1000 | 26 per 1000 (10 to 64) | | | |

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Blindness is missing in some research articles
2 Total population size is less than 400

**Figure 15:** Grading evaluation chart of evidence quality.

---

*Evidence-Based Complementary and Alternative Medicine* 11
inhibit glucosidase and plays a role in lowering blood sugar [41]. The combined use of various drugs can play a role in regulating the body and has obvious therapeutic effects on stress hyperglycemia, lipid peroxide after abnormal glucose metabolism, and insulin-damaging hyperglycemia [42].

In this study, after the intervention of the experimental group through Shenqi Jiangtang granules combined with conventional Western medicine treatment and the control group with only conventional Western medicine treatment, the main outcome indicators showed a treatment trend, but the improvement of the indicators of the patients in the experimental group was significantly greater than that of the control group. For the patients in the group, the difference in data was statistically significant ($P < 0.05$). First, it shows the therapeutic effect of Western medicine conventional hypoglycemic drugs on type 2 diabetes and also suggests that Shenqi Jiangtang granules can significantly improve the effectiveness of clinical treatment based on Western medicine treatment and further improve PBG, FBG, HbA1c, and other related indicators.

Limitations in our meta-analysis should be considered as follows: First of all, the literature was included with low quality and small sample sizes. Also, the research methods were not reported in details, thereby making bias risk assessment difficult. Particularly, none of the studies provided any detail on single or double blinding and allocation concealment, which indicated poor quality of the methodology and led to high risk of selection and measurement bias. Secondly, although we adopted an adequate search strategy to minimize publication bias, some potential biases may still exist because of language restriction. Thirdly, drug safety is a key factor in clinical applications, but only four RCTs described adverse reactions or events. Therefore, the safety of using Shenqi Jiangtang granule should be validated in future to bring more convincing evidence. Besides, none of the studies reported end-point outcomes such as the incidence of type 2 diabetes, mortality rate, and life quality, thus making the assessment of the long-term efficacy of Shenqi Jiangtang granule difficult, which will affect the further development of drugs.

Findings from this meta-analysis illustrate that Shenqi Jiangtang granule in the treatment of type 2 diabetes mellitus may be effective. Because of the poor methodological quality and small sample sizes, further validation is essential. Therefore, we recommend the conduction of multicenter, large-sample, and randomized controlled double-blind trials to provide more accurate and reliable evidence for clinical research.

Data Availability

The data used to support the findings of this study are included within the article.

Disclosure

Ruo-Lan Li, Tai-Wei Dong, and Ji-Gang Wei are considered co-first authors.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

Ruo-Lan Li, Tai-Wei Dong, and Ji-Gang Wei contributed equally to this work.

Acknowledgments

This study was supported by the Subject Innovation Team of Shaanxi University of Chinese Medicine (2019-QN02) and Innovation Team of The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine (2020XKTD-A04).

References

[1] J. Xu, F. Lian, L. Zhao et al., “Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula,” The ISME Journal, vol. 9, no. 3, pp. 552-562, 2015.
[2] A. Worku, S. Mekonnen Abebe, and M. J. S. Wassie, “Dietary practice and associated factors among type 2 diabetic patients: a cross sectional hospital based study,” Addis Ababa, Ethiopia, vol. 4, no. 1, p. 15, 2015.
[3] Y. Xu, L. Wang, J. He et al., “Prevalence and control of diabetes in Chinese adults,” JAMA, vol. 310, no. 9, pp. 948-959, 2013.
[4] J. F. Fu, L. Liang, C. X. Gong et al., “Status and trends of diabetes in Chinese children: analysis of data from 14 medical centers,” World Journal of Pediatrics, vol. 9, no. 2, pp. 127-134, 2013.
[5] Diabetes Association of Chinese Medical Association, “Guidelines for the prevention and treatment of type 2 diabetes in China (2013 Edition),” Chinese Journal of Endocrinology and Metabolism, vol. 30, no. 10, pp. 26-89, 2014.
[6] L. Baoen, “Relationship between deficiency of yin and yang, deficiency of Qi and Yin and chronic complications of diabetes,” Henan Traditional Chinese Medicine, vol. 6, pp. 139-140.
[7] U.C. Hong, “TCM syndrome type analysis of type 2 diabetes and its relationship with chronic complications of diabetes,” Contemporary Medicine, vol. 11, pp. 135-136.
[8] X. S. Tiantian, “Observation on the efficacy of sulodette combined with simvastatin in the treatment of diabetic lower extremity angiopathy,” World Latest Medicine Information, vol. A4, pp. 160-164.
[9] K. S. Choi, J. S. Shin, J. J. Lee et al., “In vitro trans-differentiation of rat mesenchymal cells into insulin-producing cells by rat pancreatic extract,” Biochemical & Biophysical Research Communications, vol. 330, no. 4, pp. 1299-1305, 2005.
[10] E. M. Davis, C. M. Christensen, K. K. Nystrom, P. A. Foral, and D. Chris, “Patient satisfaction and costs associated with insulin administered by pen device or syringe during hospitalization,” American Journal Of Health-System Pharmacy, vol. 65, no. 14, pp. 1347-1357, 2008.
[11] H. Inadera, “The usefulness of circulating adipokine levels for the assessment of obesity-related health problems,” International Journal Of Medical Ences, vol. 5, no. 5, pp. 248-262, 2008.
Evidence-Based Complementary and Alternative Medicine

[12] D. B. Sacks, "Amylin—a glucoregulatory hormone involved in the pathogenesis of diabetes mellitus?" Clinical Chemistry, vol. 42, no. 4, pp. 494-495, 1996.

[13] P. Das, S. Biswas, S. Mukherjee, and S. K. Bandypadhyay, "Association of oxidative stress and obesity with insulin resistance in type 2 diabetes mellitus," Mymensingh Medical Journal, vol. 25, no. 1, pp. 148-152, 2016.

[14] L. Zhao and S. Y. Wang, "Treatment frequency and long-term efficacy observation on electric pudendal nerve stimulation for stress urinary incontinence," Journal of Acupuncture and Tuina Science, vol. 11, no. 3, pp. 177–180, 2013.

[15] Y. Gu, Y. Zhang, X. Shi et al., "Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics," Talanta, vol. 81, no. 3, pp. 766–772, 2010.

[16] N. M. Geremia, T. Gordon, T. M. Brushart, A. A. Al-Majed, and V. M. K. Verge, "Electrical stimulation promotes sensory neuron regeneration and growth-associated gene expression," Experimental Neurology, vol. 205, no. 2, pp. 0–359, 2005.

[17] J. Hu, "Clinical observation on 102 cases of type 2 diabetes treated with Shenqi Jiangtang granules," Nei Mongol Journal of Traditional Chinese Medicine, vol. 35, pp. 35-36.

[18] Diabetes Association of Chinese Medical Association, "Guidelines for the prevention and treatment of type 2 diabetes in China (2017)," Chinese Journal of Diabetes Mellitus, vol. 10, pp. 4–67, 2018.

[19] F. Men, "How about the quality of systematic evaluation/meta-analysis evidence in domestic nursing field?—evaluation based on grade guidelines," Chinese Journal of Evidence-Based Medicine, vol. 13, no. 11, pp. 1392–1396.

[20] G. Guyatt, A. D. Oxman, E. A. Ak et al., "Grade guidelines: I. Introduction—grade evidence summary table and result summary table," Chinese Journal of Evidence-Based Medicine, vol. 4, no. 4, pp. 383–394, 2011.

[21] L. Zhang, W. Leilei, L. Mingdong, and W. Yuanyuan, "Clinical study on Shenqi Jiangtang granules in adjuvant therapy for type 2 diabetes of qi-yin deficiency type," Journal of New Chinese Medicine, vol. 2019, no. 4, pp. 166–168, 2019.

[22] F. Sui, "Observation on the effect of Shenqi Jiangtang granule combined with western medicine in the treatment of type 2 diabetes," Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 19, no. 7, pp. 69-70.

[23] H. Liu and C. Guo, "Efficacy evaluation of metformin and Shenqi Jiangtang granules in the treatment of newly diagnosed type 2 diabetes," China Modern Doctor, vol. 55, p. 35.

[24] Y. Sun, "Clinical observation of Shenqi Jiangtang granule combined with conventional western medicine in the treatment of type 2 diabetes," Journal Of New Chinese Medicine, vol. 49, p. 54, 2017.

[25] C. Wang, "Shenqi Jiangtang Granules combined with conventional western medicine in the treatment of type 2 diabetes," Jilin Journal of Traditional Chinese Medicine, vol. 36, no. 5, pp. 36–40, 2016.

[26] H. Yang, "The effect of Shenqi Jiangtang granule combined with atorvastatin on β cell function, endothelial cell function and target organ damage in patients with type 2 diabetes mellitus and metabolic syndrome," Modern Journal of Integrated Traditional Chinese and Western Medicine, vol. 35, p. 3923, 2017.

[27] S. Chen, "Clinical study on 52 cases of type 2 diabetes treated with Shenqi Jiangtang granules and Western medicine," China Health Standard Management, vol. 9, no. 16, pp. 105-107, 2018.

[28] Y. Fan and J. Gao, "Clinical observation of Shenqi Jiangtang granule in the treatment of type 2 diabetes," China Medical Equipment, vol. 8, p. 142, 2014.

[29] Y. Zhang, "Shenqi Jiangtang granule combined with xiglitiptin metformin tablets in the treatment of type 2 diabetes," Practical Clinical Journal of Integrated Traditional Chinese and Western Medicine, vol. 19, no. 4, pp. 19–21, 2019.

[30] C. Song, "Effect of lilaluptide combined with Shenqi Jiangtang Granule on the changes of serum glycosylated hemoglobin, serum amyloid a level in acute phase and body mass index in obese patients with type 2 diabetes," China Journal of Pharmaceutical Economics, vol. 13, no. 4, 2018.

[31] W. Li, "Analysis of the therapeutic effect of retaglinide combined with Shenqi liangtang granules on type 2 diabetes," Modern Practical Medicine, vol. 27, no. 5, pp. 603-604, 2015.

[32] Z. Wang, "Clinical observation of Shenqi Jiangtang granules on type 2 diabetic patients with insulin resistance," Nei Mongol Journal of Traditional Chinese Medicine, vol. 13, pp. 32–34, 2013.

[33] G. Liu, "Analysis of therapeutic effect and prognosis of Shenqi Jiangtang Granule on elderly patients with type 2 diabetes," Journal of Human Normal University (Medical Science), vol. 15, no. 2, pp. 52–54, 2018.

[34] J. W. Kim, K. M. Kang, T. K. Yoon, S. H. Shim, and W. S. Lee, "Study of circulating hepcidin in association with iron excess, metabolic syndrome, and BMP-6 expression in granulosa cells in women with polycystic ovary syndrome," Fertility & Sterility, vol. 102, no. 2, pp. 548–554, 2014.

[35] L. Zhuang, "Efficacy analysis of acarbose, metformin hydrochloride and Shenqi Jiangtang Capsule in the treatment of type 2 diabetes," Strait Pharmaceutical Journal, vol. 31, no. 11, pp. 145–146.

[36] S. Liu, "Clinical effect of basic insulin and metformin in the treatment of type 2 diabetes," Smart Healthcare, vol. 5, no. 7, pp. 81-82.

[37] L. Li, "Professor Pang Guoming, four cases of diabetes treated by attack method," Traditional Chinese Medicinal Research, vol. 3, pp. 53–55.

[38] X. S. Fanli Men and Y. Zheng, "Hypoglycemic and antioxidant effects of ginsenoside RB3 on diabetic mice," Journal of South China Agricultural University, vol. 34, no. 4, pp. 553–557.

[39] Z. D. Jingying Qiu and J. Wang, "Effect of Shenqi Jiangtang granule combined with atorvastatin on β cell function, insulin resistance and vascular endothelial cell function in type 2 diabetes mellitus with metabolic syndrome," Chinese Archives of Traditional Chinese Medicine, vol. 37, no. 7, pp. 1725–1728.

[40] L. P. Meng Ning and W. Xie, "Hypoglycemic effect of Ophiopogon japonicus extract and its mechanism of anti-insulin resistance," Medical Journal of Chinese People's Liberation Army, vol. 1, pp. 32–35.

[41] Z. Liu, "Study on serum metabolomics of Schisandra chinensis in the treatment of diabetic nephropathy in rats," Chinese Journal of Analytical Chemistry, vol. 43, no. 2, pp. 169–175.

[42] J. Yang, "Hemorheological observation of Astragalus Injection in the treatment of diabetic nephropathy," Journal of Chinese Microcirculation, vol. 2, p. 47.